title: Influenza vaccination for the pediatric patient: a focus on the new intranasal, cold-adapted, live attenuated vaccine.
abstract: FluMist is the first live attenuated, cold-adapted intranasal influenza vaccine (LAIV) approved for the prevention of influenza A and B. Clinical trials have shown that annual vaccination with LAIV is effective for the prevention of influenza. LAIV appears well tolerated in healthy patients 5-49 years of age. The most common adverse events are abdominal pain, chills, cough, diarrhea, headache, irritability, lethargy, muscle aches, otitis media, rhinitis, sinusitis, sore throat, and vomiting. FluMist has a novel intranasal route of administration that allows for influenza prevention without a painful intramuscular injection. Barriers preventing acceptance of LAIV include defining the appropriate patient population, cost, and insurance coverage.
authors.affiliation: Department of Pharmacy Practice, University of Connecticut, School of Pharmacy, Storrs, Connecticut  ; Department of Pharmacy, Connecticut Children's Medical Center, Hartford, Connecticut  ; Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Connecticut School of Medicine, and Connecticut Children's Medical Center, Hartford, Connecticut.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Ellis
authors.forename: Joan C
authors.initials: JC
authors.lastname: Reilly
authors.forename: Juan C
authors.initials: JC
authors.lastname: Salazar
keywords: FluMist; Fluvirin; Fluzone; influenza; intranasal; vaccine